HBIO Bear Put Spread Strategy
HBIO (Harvard Bioscience, Inc.), in the Healthcare sector, (Medical - Instruments & Supplies industry), listed on NASDAQ.
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services that enables fundamental research, discovery, and pre-clinical testing for drug development in the United States and internationally. The company offers cellular and molecular technology instruments, such as syringe and peristaltic pump products, as well as a range of instruments and accessories for tissue and organ-based lab research, including surgical products, infusion systems, and behavior research systems; and spectrophotometers, microplate readers, amino acid analyzers, gel electrophoresis equipment, and electroporation and electrofusion instruments. It also engages in the development and manufacture of precision scientific measuring instrumentation and equipment, which cover data acquisition systems with custom amplifier configurations for cellular analysis, micro electrode array solutions for in vivo recordings, and vitro-systems for extracellular recordings; and offers preclinical products. The company markets its products through sales organizations, websites, catalogs, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories, as well as to contract research organizations, academic labs, and government researchers. It primarily sells its products under Harvard Apparatus, DSI, Ponemah, Buxco, Biochrom, BTX, and MCS brand names. The company was founded in 1901 and is headquartered in Holliston, Massachusetts.
HBIO (Harvard Bioscience, Inc.) trades in the Healthcare sector, specifically Medical - Instruments & Supplies, with a market capitalization of approximately $24.9M, a beta of 1.57 versus the broader market, a 52-week range of 2.8-9.5, average daily share volume of 54K, a public-listing history dating back to 2001, approximately 330 full-time employees. These structural characteristics shape how HBIO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.57 indicates HBIO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a bear put spread on HBIO?
A bear put spread buys an at-the-money put and sells an out-of-the-money put at a lower strike for defined risk and defined reward bounded by the strike width.
Current HBIO snapshot
As of May 15, 2026, spot at $5.94, ATM IV 200.40%, IV rank 41.34%, expected move 57.45%. The bear put spread on HBIO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 98-day expiry.
Why this bear put spread structure on HBIO specifically: HBIO IV at 200.40% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 57.45% (roughly $3.41 on the underlying). The 98-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated HBIO expiries trade a higher absolute premium for lower per-day decay. Position sizing on HBIO should anchor to the underlying notional of $5.94 per share and to the trader's directional view on HBIO stock.
HBIO bear put spread setup
The HBIO bear put spread below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With HBIO near $5.94, the first option leg uses a $5.94 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed HBIO chain at a 98-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 HBIO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Put | $5.94 | N/A |
| Sell 1 | Put | $5.64 | N/A |
HBIO bear put spread risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-put strike minus net debit.
HBIO bear put spread payoff curve
Modeled P&L at expiration across a range of underlying prices for the bear put spread on HBIO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use bear put spread on HBIO
Bear put spreads on HBIO reduce the cost of a bearish HBIO stock position by selling a lower-strike put; suited to moderate-decline theses where price reaches but does not vastly exceed the short strike.
HBIO thesis for this bear put spread
The market-implied 1-standard-deviation range for HBIO extends from approximately $2.53 on the downside to $9.35 on the upside. A HBIO bear put spread caps both the risk and the reward of a bearish position; relative to an outright long put on HBIO, the spread reduces the cost basis but limits the maximum profit to the strike width minus net debit. Current HBIO IV rank near 41.34% is mid-range against its 1-year distribution, so the IV signal is neutral; the bear put spread thesis on HBIO should anchor more to the directional view and the expected-move geometry. As a Healthcare name, HBIO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to HBIO-specific events.
HBIO bear put spread positions are structurally moderately bearish; the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. HBIO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move HBIO alongside the broader basket even when HBIO-specific fundamentals are unchanged. Long-premium structures like a bear put spread on HBIO are particularly exposed to IV-crush risk through scheduled events (earnings, FDA decisions, central-bank meetings) where IV typically contracts post-event regardless of the directional outcome. Always rebuild the position from current HBIO chain quotes before placing a trade.
Frequently asked questions
- What is a bear put spread on HBIO?
- A bear put spread on HBIO is the bear put spread strategy applied to HBIO (stock). The strategy is structurally moderately bearish: A bear put spread buys an at-the-money put and sells an out-of-the-money put at a lower strike for defined risk and defined reward bounded by the strike width. With HBIO stock trading near $5.94, the strikes shown on this page are snapped to the nearest listed HBIO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are HBIO bear put spread max profit and max loss calculated?
- Max profit equals strike width minus net debit times 100; max loss equals net debit times 100. Breakeven is long-put strike minus net debit. For the HBIO bear put spread priced from the end-of-day chain at a 30-day expiry (ATM IV 200.40%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a HBIO bear put spread?
- The breakeven for the HBIO bear put spread priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current HBIO market-implied 1-standard-deviation expected move is approximately 57.45%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a bear put spread on HBIO?
- Bear put spreads on HBIO reduce the cost of a bearish HBIO stock position by selling a lower-strike put; suited to moderate-decline theses where price reaches but does not vastly exceed the short strike.
- How does current HBIO implied volatility affect this bear put spread?
- HBIO ATM IV is at 200.40% with IV rank near 41.34%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.